Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22636830 | 0.91 | TLR2 (0.57) | TNFTLR2KMT2AMDM4TP53 | |
| SCHEMBL18708299 | 0.91 | TLR2 (0.57) | TNFTLR2KMT2AMDM4TP53 | |
| SCHEMBL18689465 | 0.91 | TLR2 (0.57) | TNFTLR2KMT2AMDM4TP53 | |
| SCHEMBL22636832 | 0.91 | TLR2 (0.57) | TNFTLR2KMT2AMDM4TP53 | |
| SCHEMBL22636827 | 0.91 | TLR2 (0.57) | TNFTLR2KMT2AMDM4TP53 | |
| SCHEMBL30141761 | 0.91 | TLR2 (0.57) | TNFTLR2KMT2AMDM4TP53 | |
| SCHEMBL18689466 | 0.91 | TLR2 (0.57) | TNFTLR2KMT2AMDM4TP53 | |
| SCHEMBL22636828 | 0.91 | TLR2 (0.57) | TNFTLR2KMT2AMDM4TP53 | |
| SCHEMBL2453440 | 0.87 | TLR2 (0.51) | TNFTLR2 | |
| SCHEMBL2417308 | 0.87 | TLR2 (0.51) | TNFTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016918-B2 | Peptide-containing adjuvant compounds having peg spacers | UNIVERSITEIT LEIDEN (NL) | 2024-06-25 | — | — | US | disclosed |
| US-20200188512-A1 | ADJUVANT COMPOUNDS | UNIVERSITEIT LEIDEN (NL) | 2020-06-18 | — | — | US | disclosed |
| EP-3615062-A1 | ADJUVANT COMPOUNDS | Universiteit Leiden (NL) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018197582-A1 | ADJUVANT COMPOUNDS | UNIVERSITEIT LEIDEN (NL) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016918-B2 | Peptide-containing adjuvant compounds having peg spacers | MYD88, CD74, NGLY1 | TNF 364/4885TLR2 28/4885KMT2A 3733/4885 |
| US-20200188512-A1 | ADJUVANT COMPOUNDS | MYD88, CD74, TLR3 | TNF 407/4885TLR2 13/4885KMT2A 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.